OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

HTML

Year: 2011
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2011.35.6295
Authors: Roberto Pili, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasileios J. Assikis, Anders Björk, Örjan Nordle, Goran Forsberg, Michael A. Carducci, Andrew J. Armstrong
Institutions: Uppsala University, Roswell Park Comprehensive Cancer Center, Uppsala University Hospital, Johns Hopkins University, University of Pittsburgh, University of Chicago, Piedmont Cancer Institute, Active Biotech (Sweden), Sidney Kimmel Comprehensive Cancer Center
Language: English

Topic: Prostate Cancer Treatment and Research
Subfield: Cancer Research
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: tasquinimod, castration-resistant prostate cancer, metastatic prostate cancer, S100A9, progression-free survival, disease progression, bone metastasis, visceral metastases, nodal metastases, alkaline phosphatase, prostate-specific antigen, adverse events, deep vein thrombosis
SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute
Award: Regional Oncology Research Center
OpenAlex ID: W2130088545
FWCI: 10.12
Cites: 24
Cited by: 215
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms